Hikma Pharmaceuticals (HIK.L)
Hikma Pharmaceuticals is a global provider of generic, branded, and injectable medicines with a significant footprint in the US and MENA markets.
What Hikma Pharmaceuticals does
Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of generic, branded, and injectable medicines. Its operations are organized into three primary business segments: Injectables, Generics, and Branded pharmaceuticals. The company maintains a strong presence across the Middle East, North Africa (MENA) region, the United States, and Europe.
Themes: generic drugs, injectable medicines, healthcare accessibility, MENA regional market
Fundamentals
- Price£15.73 as of 2026-08-03 close
- Market capn/a company fundamentals are not available for UK-listed companies in our data
- 1-year return-18.9% 2025-08-01 close £19.39 → 2026-08-03 close £15.73
- P/En/a company fundamentals are not available for UK-listed companies in our data
- Net marginn/a company fundamentals are not available for UK-listed companies in our data
- Gross marginn/a company fundamentals are not available for UK-listed companies in our data
- ROEn/a company fundamentals are not available for UK-listed companies in our data
- Debt / equityn/a company fundamentals are not available for UK-listed companies in our data
- Revenue growth (YoY)n/a company fundamentals are not available for UK-listed companies in our data
- Revenue CAGR (3y)n/a company fundamentals are not available for UK-listed companies in our data
- Betan/a we do not track a market benchmark for UK-listed companies
Dividend: company fundamentals are not available for UK-listed companies in our data.
How Hikma Pharmaceuticals looks technically
Hikma Pharmaceuticals (HIK.L) is trading 2.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 252 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day high about 20 trading days ago. It is 27.3% below its highest point of the past year. Trading volume is unusually light — only about 0% of its 30-day average.
Trend
| Distance from the 200-day | +2.4% | it is trading 2.4% above its 200-day average, the long-term trend line — a longer-term uptrend |
|---|---|---|
| 50-day moving average | £15.20 | its average price over the last 50 trading days — a short-term trend line — is £15.20 |
| 200-day moving average | £15.37 | its average price over the last 200 trading days — the long-term trend line — is £15.37 |
| Since the 50/200 cross | 252 sessions | its 50-day average crossed below its 200-day average about 252 trading days ago — a "death cross", a bearish long-term signal |
| Above the 200-day after a dip | +2.4% | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 2.4% above |
| Trend strength (14-day ADX) | 16.2 | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend |
Momentum
| 14-day RSI | 52.9 | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) |
|---|---|---|
| Since the MACD crossed zero | 1 session | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) |
Range
| 52-week high | £21.64 | its highest closing price over the past year (about 252 trading days) was £21.64 |
|---|---|---|
| From the 52-week high | -27.3% | it is 27.3% below its 52-week high (its highest price of the past year) |
| Above the 52-week low | +32.5% | it is 32.5% above its 52-week low (its lowest price of the past year) |
| Below the 52-week high | 27.3% | it is 27.3% below its highest point of the past year |
| Since a 20-day breakout | 20 sessions | it made a new 20-day high about 20 trading days ago |
| Since a 55-day breakout | 20 sessions | it made a new 55-day high about 20 trading days ago |
| All-time high | £27.68 | its highest closing price on record is £27.68 (set on 2020-11-05) |
| From the all-time high | -43.2% | it is 43.2% below its all-time high |
| All-time low | £5.09 | its lowest closing price on record is £5.09 (set on 2010-01-05) |
| Above the all-time low | +209.0% | it is 209.0% above its all-time low |
Volatility
| Band width vs its own 6 months | 48th percentile | day-to-day price swings are about average versus its own recent 6-month history |
|---|---|---|
| Bollinger bands (20-day, ±2σ) | £14.94 – £15.76 – £16.58 | most of its recent trading has stayed between about £14.94 and £16.58 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles |
Volume
| Volume vs its 30-day average | 0.00× | trading volume is unusually light — only about 0% of its 30-day average |
|---|
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-03. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["Intense price competition in the generic pharmaceutical market","Regulatory risks and compliance requirements regarding drug approvals and manufacturing standards","Supply chain disruptions and fluctuations in raw material costs"]
Competitors & peers
- Teva Pharmaceutical Industries (TEVA)
- Viatris (VTRS)
- Sandoz (SDZNY)
- Fresenius Kabi (FRE.DE)
- Pfizer (PFE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare HIK.L vs…
Frequently asked questions
What does Hikma Pharmaceuticals (HIK.L) do?
Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of generic, branded, and injectable medicines. Its operations are organized into three primary business segments: Injectables, Generics, and Branded pharmaceuticals. The company maintains a strong presence across the Middle East, North Africa (MENA) region, the United States, and Europe.
Who are Hikma Pharmaceuticals's (HIK.L) competitors?
Notable peers of Hikma Pharmaceuticals (HIK.L) include Teva Pharmaceutical Industries, Viatris, Sandoz, Fresenius Kabi and Pfizer. This peer set is informational only — not financial advice.
Is Hikma Pharmaceuticals (HIK.L) overbought or oversold right now?
Hikma Pharmaceuticals (HIK.L) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-08-03). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on HIK.L come from?
Fundamentals and prices come from market data. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from market data, shown with their as-of date.